Drug/Small Molecule:
dinoprost tromethamine

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug/small molecule. To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Dinoprost, trometamol salt
  • PGF2-alpha THAM
  • PGF2alpha THAM
  • Prostaglandin F2-alpha THAM
  • Prostaglandin F2a tromethamine
  • Prostaglandin F2alpha tham
  • Prostin F2 Alpha
Trade Names
  • Dinolytic
  • Ensaprost
  • Lutalyse
  • Panacelan F tromethamine salt
  • Pronalgon F
  • Prostalmon F
  • Zinoprost
Brand Mixture Names

PharmGKB Accession Id:
PA164781385

Description

The tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine.

Source: Drug Bank

Indication

Used for aborting second-trimester pregnancy (between the twelfth to eighteenth week of gestation) and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life. Also used at low-doses for medically indicated induction of labor at term. Also injected intra-arterially for use as a vasodilator to assist in angiography.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Dinoprost tromethamine appears to act directly on the myometrium, but this has not been completely established. Dinoprost stimulates myometrial contractions (via its interaction with the prostaglandin receptors) in the gravid uterus that are similar to the contractions that occur in the term uterus during labor. These contractions are usually sufficient to cause abortion. Uterine response to prostaglandins increases gradually throughout pregnancy. Dinoprost also facilitates cervical dilatation and softening.

Source: Drug Bank

Pharmacology

Dinoprost tromethamine is the tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha. Prostaglandin F2 alpha has several pharmacologic effects on the female reproductive system, including stimulation of myometrial activity, relaxation of the cervix, inhibition of steroidogenesis by corpora lutea, and can potentially lyse corpora lutea.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Enzymatic dehydrogenation primarily in the maternal lungs and also in the liver.

Source: Drug Bank

Absorption

Slowly absorbed from the amniotic fluid into systemic circulation.

Source: Drug Bank

Half-Life

The half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.

Source: Drug Bank

Toxicity

Although overdose by intra-amniotic administration of dinoprost has not been reported, exaggeration of the nausea, vomiting, and diarrhea that occur with normal doses would be expected.

Source: Drug Bank

Chemical Properties

Chemical Formula

C24H45NO8

Source: Drug Bank

Isomeric SMILES

CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O

Source: Drug Bank

NC(CO)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O

Source: Drug Bank

Canonical SMILES

OCC(N)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]

Source: Drug Bank

Average Molecular Weight

475.616

Source: Drug Bank

Monoisotopic Molecular Weight

475.314517421

Source: Drug Bank

LinkOuts

DrugBank:
DB01160
KEGG Drug:
D01352
PubChem Compound:
5282415
PubChem Substance:
213676
46509164
Drugs Product Database (DPD):
813605
ChemSpider:
4445570
Therapeutic Targets Database:
DAP000826

Clinical Trials

These are trials that mention dinoprost tromethamine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.